AVM0703
Phase 2Small molecule
AVM0703 is one of 5 small molecule programs targeting Lymphoid Malignancies. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Lymphoid Malignancies
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Tazverik
EEpizyme, Inc.
Phase 1
Folotyn
AAcrotech Biopharma Inc.
Preclinical
AVM0703
AAVM Biotechnology Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AVM0703. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAVM Biotechnology Inc